Literature DB >> 8564093

Interleukin-12 inhibits antigen-induced airway hyperresponsiveness in mice.

J C Kips1, G J Brusselle, G F Joos, R A Peleman, J H Tavernier, R R Devos, R A Pauwels.   

Abstract

The airway inflammation observed in allergic asthma is thought to be orchestrated by an antigen-driven T-helper-2 (Th2) lymphocyte response. In vitro data indicate that the presence of interleukin-12 (IL-12) during the primary stimulation of T-lymphocytes with antigen favors the development of Th1 cells. The aim of the present study was to examine the effect of IL-12 in vivo on antigen-induced airway changes in a murine model. C57BL/6 mice were actively sensitized to ovalbumin; 14 d later, they were exposed daily for 7 d to aerosolized ovalbumin. This resulted in airway eosinophilia, production of ovalbumin-specific IgE, and airway hyperresponsiveness to carbachol. Administration of recombinant murine IL-12 (rmIL-12) during the active immunization prevented these antigen-induced changes. In contrast, administration of rmIL-12 to actively immunized mice during the daily aerosol exposure (but not at the time of immunization) abolished airway eosinophilia and hyperresponsiveness without influencing the production of specific IgE. These results suggest that IL-12 can suppress antigen-induced airway changes despite the presence of circulating specific IgE.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8564093     DOI: 10.1164/ajrccm.153.2.8564093

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  23 in total

Review 1.  Cytokines in asthma.

Authors:  K F Chung; P J Barnes
Journal:  Thorax       Date:  1999-09       Impact factor: 9.139

Review 2.  Emerging roles of T helper subsets in the pathogenesis of asthma.

Authors:  Douglas M Durrant; Dennis W Metzger
Journal:  Immunol Invest       Date:  2010       Impact factor: 3.657

3.  Reduced production of interleukin 12 by interferon gamma primed alveolar macrophages from atopic asthmatic subjects.

Authors:  M J Plummeridge; L Armstrong; M A Birchall; A B Millar
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

Review 4.  Importance of cytokines in murine allergic airway disease and human asthma.

Authors:  Fred D Finkelman; Simon P Hogan; Gurjit K Khurana Hershey; Marc E Rothenberg; Marsha Wills-Karp
Journal:  J Immunol       Date:  2010-02-15       Impact factor: 5.422

5.  Characterization of airway and vascular responses in murine lungs.

Authors:  H D Held; C Martin; S Uhlig
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

6.  Alveolar macrophages from allergic lungs are not committed to a pro-allergic response and can reduce airway hyperresponsiveness following ex vivo culture.

Authors:  P Pouliot; A Spahr; E Careau; V Turmel; E Y Bissonnette
Journal:  Clin Exp Allergy       Date:  2008-01-14       Impact factor: 5.018

7.  Interleukin-12 suppresses filaria-induced pulmonary eosinophilia, deposition of major basic protein and airway hyperresponsiveness.

Authors:  R K Mehlotra; L R Hall; A W Higgins; I A Dreshaj; M A Haxhiu; J W Kazura; E Pearlman
Journal:  Parasite Immunol       Date:  1998-10       Impact factor: 2.280

Review 8.  The increased prevalence of allergy and the hygiene hypothesis: missing immune deviation, reduced immune suppression, or both?

Authors:  Sergio Romagnani
Journal:  Immunology       Date:  2004-07       Impact factor: 7.397

9.  Interleukin-12-independent down-modulation of cockroach antigen-induced asthma in mice by intranasal exposure to bacterial lipopolysaccharide.

Authors:  Steven K Lundy; Aaron A Berlin; Nicholas W Lukacs
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

10.  Influence of epinastine hydrochloride, an H1-receptor antagonist, on the function of mite allergen-pulsed murine bone marrow-derived dendritic cells in vitro and in vivo.

Authors:  Ken-Zaburo Oshima; Kazuhito Asano; Ken-Ichi Kanai; Miyuki Suzuki; Harumi Suzaki
Journal:  Mediators Inflamm       Date:  2009-04-09       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.